Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Form 483
Pharma
Eisai, ex-NMPA official, Pfizer-Summit—Fierce Pharma Asia
Eisai initiated a U.S. restructuring program. A former China NMPA deputy director is under investigation. Pfizer formed a collaboration with Summit.
Angus Liu
Feb 28, 2025 8:45am
FDA hits Piramal with 6-observation Form 483 at India API plant
Feb 26, 2025 10:22am
FDA scrutinizes Novo on production issues at semaglutide plant
Oct 31, 2024 9:33am
FDA found contamination issues at Thermo Fisher NC plant
Oct 11, 2024 10:42am
Daiichi, Eisai, Granules—Fierce Pharma Asia
Sep 20, 2024 10:16am
Granules receives Form 483 over poor document controls and more
Sep 19, 2024 10:11am
